Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer

NCT05075577 is registered in ClinicalTrials.gov with ESSA Pharmaceuticals as lead sponsor.

NCT NCT05075577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05075577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
ESSA Pharmaceuticals
Phase
Phase 1/2
Overall status
Terminated
Start date
December 21, 2021
Completion date
January 14, 2025
Enrollment
77 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer